Correlation ofTP53andMDM2genotypes with response to therapy in sarcoma

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines

(2011) Hege O Ohnstad et al.   BMC CANCER

The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

(2011) Stian Knappskog et al.   CANCER CELL

p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors

(2010) Baozong Li et al.   CELL CYCLE

Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis

(2010) M. Ito et al.   CLINICAL CANCER RESEARCH

Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes

(2010) Magali Olivier et al.   CURRENT OPINION IN ONCOLOGY

Effect of TP53 Arg72Pro and MDM2 SNP309 Polymorphisms on the Risk of High-Grade Osteosarcoma Development and Survival

(2009) G. Toffoli et al.   CLINICAL CANCER RESEARCH

Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort

(2009) Laura Ottaviano et al.   GENES CHROMOSOMES & CANCER

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

(2008) I. Seyfried et al.   BLOOD

Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival

(2008) Silje H. Nordgard et al.   INTERNATIONAL JOURNAL OF CANCER

Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status

(2008) Ye Xu et al.   INTERNATIONAL JOURNAL OF CANCER

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon

(2008) Antoine Italiano et al.   INTERNATIONAL JOURNAL OF CANCER